PFA
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Amerise Biosciences (formerly Amradeep Industries) announced unaudited results for the quarter and nine months ended 31 December 2025. The company reported zero revenue from operations, with total income of Rs 4.49 lakh in Q3 FY26 (entirely from 'other income') and Rs 17.60 lakh for 9M FY26. Profit after tax was Rs 0.97 lakh for Q3, but the company posted a loss of Rs 4.07 lakh for the nine-month period, narrower than the Rs 9.83 lakh loss in the corresponding 9M of the previous year. Total expenses for 9M FY26 stood at Rs 21.67 lakh. The board also accepted the resignation of Mr. Dinesh Rathod as Whole-time Director & CFO (citing pre-occupation with other work) and appointed 25-year-old Mr. Albert Hines, with about 3 years of finance experience, as the new Whole-time Director and CFO effective 2 February 2026. The statutory auditors (Bipin & Co.) issued an unmodified limited review report with no qualifications.
The company continues to generate no operating revenue and is dependent on 'other income' to stay afloat, with negative other equity of Rs 122.71 lakh against share capital of Rs 660.69 lakh — investors should view this as a high-risk, micro-cap situation. The CFO change and the very young, lightly experienced replacement could raise governance concerns for shareholders.